Tocilizumab for COVID-19 Acute Respiratory Distress Syndrome: Outcomes Assessment Using the WHO Ordinal Scale

Introduction Cytokine release syndrome in COVID-19 is characterized by hyperinflammation, which manifests as acute respiratory distress syndrome (ARDS), multiorgan failure, and high inflammatory parameters. Tocilizumab, an interleukin 6 (IL-6) antagonist has been used in COVID-19 ARDS with conflicti...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cureus
Main Authors: Nasir, Nosheen, Mahmood, Faisal, Habib, Kiren, Khanum, Iffat, Jamil, Bushra
Format: Artigo
Jezik:Inglês
Izdano: Cureus 2020
Teme:
Internal Medicine
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7829612/
https://ncbi.nlm.nih.gov/pubmed/33510989
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.12290
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki